APSR2026-460

 
Late-Breaking
Submitted
Oral Presentation
AO33-002
 
 
https://storage.unitedwebnetwork.com/files/1285/1220523-46903-1220523-46903-APSR 2026_MDR-TB Catastrophic Cost_434167_439920.pptx
Format: PPTX Only
 
Format: PDF Only
06. Tuberculosis
5

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Lisa Kawatsu - Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan
Kazuhiro Uchimura * Research Institute of Tuberculosis Department of Epidemiology and Clinical Research Tokyo Japan
Ko Sugiura - National Institute of Infectious Diseases Center for Emergency Preparedness and Response Tokyo Japan
Akira Shibanuma - University of Tokyo Department of Community and Global Health Tokyo Japan
Takashi Yoshiyama - Fukujuji Hospital Fukujuji Hospital Tokyo Japan
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Kazuhiro
Uchimura
uchimura@jata.or.jp
+819053011006
41-50
Japan
Original Research
First National Catastrophic Cost Survey among MDR-TB patients in Japan
Maximum 25 words
Abstract Content
In Japan, 35 patients were diagnosed with MDR-TB in 2023. National heath insurance and public subsidy fully cover for hospitalization, and 95% of outpatient treatment cost for TB. However, the cost of second-line drugs often exceeds that covered by insurance and subsidy, placing significant burden on patients. We therefore conducted a first national survey on catastrophic costs of MDR-TB in Japan.
Design: Cross-sectional study. MDR-TB patients meeting the following inclusion criteria -aged 18 years old or above, diagnosed with MDR-TB and on treatment on MDR-TB for two weeks or longer, and consented to participate in the study, were recruited via specialist TB hospitals. Face-to-face, structured interview using modified version of WHO’s catastrophic cost survey questionnaire was conducted. Direct medical and non-medical cost and indirect cost were calculated, and divided by household income to estimate the percentage of total costs incurred by MDR-TB patients in relation to self-reported household income. Percentage greater than 20% was defined as catastrophic cost.
In total, 26 MDR-TB patients were interviewed. 16 were foreign-born, and the average age in years was 62.1 among Japan-born and 35.9 among foreign-born patients. Data of 23, whose treatment details were available, were analyzed. 20 were prescribed BDQ and DLM. Average treatment duration was 567 days. Average direct medical, non-medical and indirect cost were 429,018 JPY (approx. 2,860 USD), 93,403 JPY (approx. 623 USD) and 439,565 JPY (approx. 2,930 USD) respectively. Percentage total costs to household income exceeded 20% among 48% of the patients. The proportions of those experiencing catastrophic cost were slightly higher among foreign-born as compared with Japan-born patients (44% vs 40%), and among those aged under 60 years old (44% vs 20%).
Our study revealed that approximately half of the patients experienced catastrophic cost, 45% of which was attributable to direct medical cost despite UHC in Japan.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
tuberculosis, multi-drug resistant tuberculosis, cost, Japan
maximum 3 keywords and no abbreviations, separated by commas
The study was funded by KAKENHI Grant no. 23K09709. The authors would like to thank all those patients who participated in the study, Drs Y.Tamura, T.Nakagawa, K.Miyazaki, T.Nakano for their generous support, and the interpreters who accompanied interviews with non-Japanese speaking patients.
306